To determine whether 1,5-benzothiazepine Ca 2ϩ channel blocker approaches its binding domain within the cardiac Ltype Ca 2ϩ channel from inside or outside of the membrane, we tested the effects of a novel potent 1,5-benzothiazepine derivative (DTZ323) and its quaternary ammonium derivative (DTZ417) on guinea pig ventricular myocytes by using the whole-cell patch-clamp technique. The extracellular application of DTZ417 suppressed the L-type Ca 2ϩ channel currents (I Ca(L) ) with an IC 50 value of 1.2 Ϯ 0.02 M, which was close to the IC 50 value of diltiazem (0.63 Ϯ 0.01 M). The suppression of I Ca(L) by DTZ417 was voltage and use dependent but lacked tonic block, which allowed us to investigate the onset of the effect on I Ca(L) by changing the holding potential (HP) from Ϫ90 to Ϫ50 mV in the presence of DTZ417. DTZ417 did not have significant effects on I Ca(L) at an HP of Ϫ90 mV. At Ϫ50 mV, DTZ417 (50 M) applied from the extracellular side completely suppressed I Ca(L) , whereas it had no effect from the intracellular side. DTZ323 (1 M) also inhibited I Ca(L) only from the extracellular side, without any effects by the intracellular application of Յ10 M. However, a quaternary phenylalkylamine derivative, D890 (0.1 mM), acted only from the intracellular side. These results suggest that in contrast to the phenylalkylamine binding site, in cardiac myocytes the 1,5-benzothiazepine binding site is accessible from the extracellular side of the L-type Ca 2ϩ channel.
SUMMARY
To determine whether 1,5-benzothiazepine Ca 2ϩ channel blocker approaches its binding domain within the cardiac Ltype Ca 2ϩ channel from inside or outside of the membrane, we tested the effects of a novel potent 1,5-benzothiazepine derivative (DTZ323) and its quaternary ammonium derivative (DTZ417) on guinea pig ventricular myocytes by using the whole-cell patch-clamp technique. The extracellular application of DTZ417 suppressed the L-type Ca 2ϩ channel currents (I Ca(L) ) with an IC 50 value of 1.2 Ϯ 0.02 M, which was close to the IC 50 value of diltiazem (0.63 Ϯ 0.01 M). The suppression of I Ca(L) by DTZ417 was voltage and use dependent but lacked tonic block, which allowed us to investigate the onset of the effect on I Ca(L) by changing the holding potential (HP) from Ϫ90 to Ϫ50 mV in the presence of DTZ417. DTZ417 did not have significant effects on I Ca(L) at an HP of Ϫ90 mV. At Ϫ50 mV, DTZ417 (50 M) applied from the extracellular side completely suppressed I Ca(L) , whereas it had no effect from the intracellular side. DTZ323 (1 M) also inhibited I Ca(L) only from the extracellular side, without any effects by the intracellular application of Յ10 M. However, a quaternary phenylalkylamine derivative, D890 (0.1 mM), acted only from the intracellular side. These results suggest that in contrast to the phenylalkylamine binding site, in cardiac myocytes the 1,5-benzothiazepine binding site is accessible from the extracellular side of the L-type Ca 2ϩ channel.
Three major types of Ca 2ϩ channel blockers (i.e., DHPs, PAAs, and BTZs) bind to distinct, high affinity binding sites on the ␣ 1 subunit of the L-type Ca 2ϩ channel (1) (2) (3) (4) . The binding domains for DHP and PAA have been localized using photoaffinity labeling and immunoprecipitation as well as expressed chimeric channels (5) (6) (7) (8) (9) (10) . However, photoaffinity labeling does not label the exact binding site that is critical for the pharmacological effect, and chimeric channels may alter tertiary structure. Thus, electrophysiological studies have been required for determination of the validity of the binding sites predicted by photoaffinity labeling and chimeric channel experiments.
Through electrophysiological techniques, permanently charged derivatives of DHP and PAA, which are considered to be impermeable through the cell membrane, have been used to determine the sidedness of these binding domains. These electrophysiological data have indicated that the binding domain for PAA is located on the intracellular side of the membrane in cardiac (11) and skeletal (12) myocytes, whereas the DHP binding site is accessible from the extracellular side (13) . However, the binding site for BTZ has not been identified because of a lack of high affinity ligands for the BTZ site. Results of recent photoaffinity labeling and immunoprecipitation studies have suggested that the binding site for diltiazem-like Ca 2ϩ channel blockers is located in the linker region between segments S5 and S6 of domain IV (14, 15) .
A novel potent Ca 2ϩ channel blocker, DTZ323 {(ϩ)-cis-3- Fig. 1) , has been recently introduced as the most potent BTZ derivative (16) . In rabbit crude T tubule membranes, DTZ323 exhibited complete inhibition of [ 3 H]diltiazem binding (16) . K i values indicated that DTZ323 (K i ϭ 6.6 nM) was 48 times more potent than diltiazem. The specific binding of [ 3 H]DTZ323 to the membranes was saturable and (17) . Thus, the affinity of DTZ417 for the BTZ binding site is sufficiently high to be useful for localizing the BTZ binding site. The aim of this study was to determine the side of the transmembrane L-type Ca 2ϩ channel protein from which BTZ Ca 2ϩ channel blockers gain access to the binding site. We applied DTZ417 from inside or outside of the cardiac myocytes, and we demonstrated that DTZ417 suppresses I Ca(L) preferentially from the outside of the membrane. We conclude that the BTZ binding site localizes on the extracellular side of the ␣ 1 subunit of cardiac L-type Ca 2ϩ channel.
mM MgCl 2 , 10 mM glucose, 5 mM HEPES, pH 7.4 adjusted with NaOH). After gigaseal formation and rupture of the membrane patch, the external solution was changed to the Na ϩ /K ϩ -free solution containing 120 mM tetraethylammonium chloride, 4 mM CsOH, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM glucose, and 5 mM HEPES, pH 7.4 adjusted with HCl.
Patch-clamp recording. Currents were recorded using the whole-cell configuration of the patch-clamp technique (21) . The cells were placed in a chamber (volume, 0.3 ml) attached to the stage of an inverted microscope (IMT-2; Olympus, Tokyo, Japan). The tip resistances of the fire-polished microelectrodes (borosilicate glass) were 1.5-3.3 M⍀ when filled with the internal solution. Series resistance was within three times the tip resistance of the patch electrodes. Recordings were carried out using an Axopatch 1C amplifier (Axon Instruments, Burlingame, CA) with a 100-M⍀ headstage, low-pass filtered at 1 or 2 kHz, and digitized at 10 kHz. The pCLAMP software (version 5.5, Axon Instruments) was used to generate voltage-clamp protocols and acquire data.
For internal application, the diffusion half-time of DTZ417 was estimated to be 24 min according to the methods of Pusch and Neher (22) with the average membrane capacitance of the cells (80 pF) and a molecular mass of DTZ417 (M r 578.71).
Data analysis. All data were digitized online, stored on a computer hard disk, and analyzed using the pCLAMP software. Peak detection was performed with Clampan software, and the rate of inactivation of I Ca(L) was calculated with Clampfit programs. When I Ca(L) was measured, leak subtraction was performed either by subtracting the current measured in the presence of 0.1 mM CdCl 2 or by using the P/-4 protocol. In graphs in which the data points represent the results of multiple experiments, the data points were expressed as mean Ϯ standard error. In some of figures, capacitative currents of traces are truncated when they exceeded 500 pA.
Steady state inactivation curves were fitted using SigmaPlot software (Jandel Scientific, San Rafael, CA). Curve fitting for the doseresponse curves was performed, and IC 50 values were calculated using GraphPAD Prism (GraphPAD Software, San Diego, CA).
Statistical significance was assessed with Student's t test for simple comparisons or analysis of variance with Bonferroni's multiple t 
Results
The effects of DTZ417 on I Ca(L) are summarized in Fig. 2 . To determine the effects of DTZ417 on the voltage dependence of I Ca(L) ( Fig. 2A) , I-V relationships were obtained in the absence of DTZ417 and after the blocking action had reached steady state by applying test pulses to ϩ10 mV at 0.067 Hz in the presence of DTZ417 (5 M). To avoid further accumulation of the use-dependent block by DTZ417, test pulses were applied at a low frequency of 0.033 Hz, which did not allow recovery from the suppression of I Ca(L) by DTZ417
at an HP of Ϫ50 mV. DTZ417 markedly suppressed the amplitude of peak I Ca(L) without changing the voltage dependence of the I-V relationships.
Fig . 2B shows the concentration-response curve for DTZ417 that was obtained after I Ca(L) had reached its steady state level in the presence of given concentrations of DTZ417. The resulting IC 50 value was 1.2 Ϯ 0.02 M (30 cells), which was very close to the IC 50 value of diltiazem (0.63 Ϯ 0.01 M). The tertiary ammonium derivative DTZ323 also suppressed I Ca(L) with an IC 50 value of 26 Ϯ 0.08 nM under the same condition. Neither DTZ323 nor DTZ417 changed the rate of the inactivation of I Ca(L) significantly under this condition (Fig. 2, C and D) .
The interaction between a Ca 2ϩ channel blocker and Ltype Ca 2ϩ channels is modulated by the state of the channel or by the transmembrane potential, thus showing voltage dependence, use dependence, or both. The effects of DTZ417 (50 M) on the voltage dependence of the availability of Ltype Ca 2ϩ channels are shown in Fig. 3 . The extent of the inactivation of I Ca(L) was determined by a double-pulse protocol at a frequency of 0.033 Hz. At Ϫ90 mV, application of DTZ417 for 3 min produced little tonic block, suggesting that DTZ417 hardly binds to the resting state of the channel. Curves in Fig. 3 were fitted to Boltzmann's distribution:
where V 0.5 is the midpotential and k is the slope of the curve. The mean control values for V 0. 5 and k in four cells were Ϫ18.4 Ϯ 2.3 mV and 3.6 Ϯ 0.5, respectively. Application of DTZ417 shifted the V 0.5 value to Ϫ29.2 Ϯ 3.3 mV (Student's t test, p Ͻ 0.01) without changing the slope factor (4.5 Ϯ 1.7).
The use-dependent block by extracellularly applied DTZ417 (50 M) was investigated (Fig. 4) . At an HP of Ϫ50 mV, the amplitude of I Ca(L) decreased rapidly during successive stimulation in a use-dependent manner. At the more negative HP of Ϫ90 mV, less accumulation of block of I Ca(L) was observed. The degree of the use-dependent block, therefore, depended on the HP, as is the case with other Ca To compare the onset of the effects of drugs on I Ca(L) produced by extracellular and intracellular applications of drugs ( Fig. 5-7) . we took advantage of the voltage dependence and the exclusive use dependence of DTZ417 and DTZ323. Thus, we used the voltage protocol (Fig. 4) described by Kass et al. (13) and Adachi-Akahane et al. (19) with a small modification as follows: First, the cell was maintained at an HP of Ϫ90 mV. I Ca(L) was elicited by depolarizing pulses (200 msec) to ϩ10 mV at 0.067 Hz for 4 -6 min until I Ca(L) became stable. Then, the frequency was increased to 0.2 Hz, and the cell was stimulated for 2 min until I Ca(L) became stable. The external solution with or without the drug was perfused for an additional 4 min with continuous application of test pulses. Then, the test pulse was stopped, and the HP was changed to Ϫ50 mV. After 10 sec, test pulses at 0.2 Hz were started again, and changes in the peak I Ca(L) amplitudes were measured for 4 min (test period). For intracellular drug application, drugs were dissolved in the pipette solution, and the same protocol was carried out. We estimated the diffusion rate of the intracellularly applied drugs according to the method of Pusch and Neher (22) . The intracellular concentration of DTZ417 at 12-20 min after the membrane rupture was calculated to be 29 -44% of the concentration given in patch pipettes. Data were obtained only from the cells in which the run-down of the peak I Ca(L) amplitudes measured at HP Ϫ90 mV during 2 min just before the test period was Ͻ10%. control, five cells). The intracellularly applied D890 (0.1 mM) did not accelerate the decay rate of the first I Ca(L) measured at the beginning of the test period (Fig. 6B, b) and did not change the amplitude of I Ca(L)90 (Ϫ596.7 Ϯ 44.6 pA). The intracellular concentration of D890 at 12-20 min after the membrane rupture was calculated to be 30 -45% of the concentration given in patch pipettes. We confirmed that D890 acts only from the inside of the cardiac membrane, as Hescheler et al. reported (11) . These results exclude the possibility that DTZ417 did not act from the inside because of its poor diffusion from the pipette. In Fig. 5A (b) , in the presence of the extracellularly applied DTZ417 (50 M), the rate of inactivation of the first I Ca(L) recorded at an HP of Ϫ50 mV was significantly faster than that of I Ca(L)90 ( ϭ 38.5 Ϯ 7.7 versus 54.7 Ϯ 8.3 msec, p Ͻ 0.05, six cells). Similarly, in Fig. 7B (b) , in the presence of the extracellularly applied DTZ323 at 1 M, the decay rate of the first I Ca(L) at Ϫ50 mV was significantly faster than that of I Ca(L)90 ( ϭ 70.5 Ϯ 6.8 msec at Ϫ90 mV versus 60.4 Ϯ 7.3 msec at Ϫ50 mV, p Ͻ 0.05, seven cells). The reason for the change of the inactivation rate of I Ca(L) is not clear. It might be due to the overlapping inward Na ϩ /Ca 2ϩ exchange current activated by Ca 2ϩ release from the sarcoplasmic reticulum (23) or to the restitution of I Ca from the use-dependent facilitation (24) . Nevertheless, it is unlikely to be due to an open-channel-blocking effect of DTZ417, which did not change the rate of inactivation of I Ca(L) when the use-dependent effect of DTZ417 was assessed at either Ϫ50 or Ϫ90 mV (Fig. 4) .
Discussion
The BTZ binding domain has been assumed to be located near the DHP and PAA binding domains because of their allosteric interactions found in radioligand studies (1) . The quaternary benzazepine, SQ32,428, which inhibited (Ϫ)-cis-[ 3 H]desmethoxyverapamil and (ϩ)-cis-[
3 H]diltiazem binding in a competitive manner, seems to be effective only from the outside of the cell membrane (25, 26) . It has been reported that the dog coronary vasodilating activities of BTZs were selective for D-cis isomer (27) . Radioligand binding experiments also showed that the binding of diltiazem to the BTZ binding site is highly stereospecific for D-cis isomer (28) . Thus, D-cis isomer of BTZ structure seems to be critical for the pharmacological effect of BTZs. DTZ417, as well as DTZ323, is a D-cis isomer of the BTZ derivatives that conserve the BTZ structures. Therefore, we used DTZ417 and DTZ323 in the current study.
To determine the sidedness of the functional binding site of BTZ Ca 2ϩ channel blocker, we used the permanently charged quaternary derivative DTZ417, which is considered to be impermeable through cell membranes. We showed that DTZ417, like DTZ323, suppresses I Ca(L) in a voltage-and use-dependent manner without tonic block from the outside (Figs. 2 and 3) . However, the quaternarization reduced the affinity of DTZ417, as is often the case with quaternary (29) . In guinea pig ventricular myocytes, the IC 50 value of DTZ417 for inhibition of I Ca(L) was 44 times higher than that of DTZ323 when measured at an HP of Ϫ50 mV (Fig. 2B) . In rabbit crude T tubule membrane, DTZ417 inhibited the specific binding of [ 3 H]DTZ323 in a competitive manner. The K i value for DTZ417 was 13 times that for DTZ323 (16) . In both cases, DTZ417 exhibited the highest affinity for L-type Ca 2ϩ channels of all BTZ quaternary derivatives studied to date.
We applied DTZ417 from the extracellular and intracellular sides of the native cardiac cell membrane. We elevated the HP from Ϫ90 to Ϫ50 mV at Ͼ11 min after membrane rupture, which should allow Ͼ29% of the pipette concentration of DTZ417 to diffuse into myocytes (22) . DTZ417 (50 M) had no effect from the inside, whereas even at 5 M, extracellularly applied DTZ417 inhibited I Ca(L) in a voltage-and use-dependent manner. However, a high concentration of DTZ417 (0.5 mM) was effective from both sides of the membrane, suggesting distinct low affinity binding sites to which DTZ417 approaches from the intracellular side.
Adachi-Akahane et al. (19) reported that the quaternary derivative of diltiazem was equally effective from both the extracellular and intracellular sides in guinea pig ventricular myocytes. Because the affinity of quaternary diltiazem for the L-type Ca 2ϩ channels is ϳ40 times lower than that of diltiazem, it required quite a high concentration (0.1-1 mM) for suppression of I Ca(L) , even at the HP of Ϫ40 mV. Such a high concentration of quaternary diltiazem could cause the secondary effect, which might be the reason for the complex result. Diltiazem was also effective from both sides of the membrane. However, the equipotent concentration for the intracellular application was 1000 times higher than that for the extracellular application (30) , suggesting that diltiazem preferentially approaches its binding site from the outside of the membrane.
Both DHP and BTZ binding sites are accessible from the extracellular side of the membrane. However, these Ca 2ϩ channel blockers seem to interact with the channel protein at different sites. Because charged DHP confer different modulatory characteristics, such as tonic blocking action (31), on L-type Ca 2ϩ channel function compared with the charged BTZ studied in the current investigation, this observation suggests that the charged drugs are acting at different sites.
The BTZ binding site has been proposed, based on the photoaffinity labeling and immunoprecipitation experiments, to be the S5-6 linker region of domain IV and/or S6 segment of domain III (14, 15) . Thus, the binding site may be localized in the channel pore or the transmembrane region. It may be the reason why DTZ323, DTZ417, and diltiazem (BTZs) have little tonic blocking effect from the extracellular side on the resting state of the channel. At potentials more depolarized than Ϫ30 mV (Fig. 3) , the change of the conformation around the pore-forming region may allow BTZs to gain access to the binding site from the outside of the membrane.
We conclude from our results that the high affinity binding domain of BTZ Ca 2ϩ channel blocker is located on the extracellular domain of the cardiac L-type Ca 2ϩ channel protein. The identification of the critical binding site for Ca 2ϩ channel blockers for suppression of I Ca(L) would be important for understanding the channel gating mechanism and pharmacology of Ca 2ϩ channel blockers.
